# US 2012/0251483 A1 · Infarction Treatment Compositions and Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251483 A1
- Document ID: US20120251483A1
- Status: Published application
- Kind: A1
- Application number: 13/430,872
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Jason A. Burdick; Robert C. Gorman; Joseph H. Gorman, III; Jamie L. Ifkovits
- Web page: https://patentgrep.com/patent/US20120251483A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/25: with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
- A61K 31/717: Celluloses
- A61K 31/722: Chitin, chitosan
- A61K 31/727: Heparin; Heparan
- A61K 31/728: Hyaluronic acid
- A61K 31/734: Alginic acid
- A61K 31/785: Polymers containing nitrogen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of treating cardiac infarction by using an injectable material to influence cardiac structure and remodeling after infarction. Also provided are kits that comprise an injectable material to influence cardiac structure.

## Claims

### Claim 1

A method of treating a subject, comprising:
delivering a monomer to cardiac tissue comprising an infarction; and
polymerizing at least a portion of the monomer to form a reinforced region of the cardiac tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cardiac tissue comprises the myocardial wall.

### Claim 3 (depends on 2)

The method of claim 2, wherein the monomer is delivered to the interior of the myocardial wall.

### Claim 4 (depends on 1)

The method of claim 1, further comprising locating the infarction within the cardiac tissue.

### Claim 5 (depends on 4)

The method of claim 4, further comprising locating the infarction within any of the left ventricle, the right ventricle, the left atrium, the right atrium, the aorta, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, further comprising locating an infarcted area of the heart or weakened area of the heart that causes a heart valve to leak.

### Claim 7 (depends on 6)

The method of claim 6, wherein the heart valve comprises the mitral valve, the tricuspid valve, or both.

### Claim 8 (depends on 4)

The method of claim 4, further comprising delivering the monomer to the infarction.

### Claim 9 (depends on 1)

The method of claim 1, wherein the monomer comprises methacrylated hyaluronic acid, methacrylated/acrylated poly(ethylene glycol), acrylated poly(ethylene glycol), methacrylated/acrylated poly(vinyl alcohol), methacrylated/acrylated chitosan, metahcrylated/acrylated cellulose, poly(n-isopropryl acrylamide), methacrylated/acrylated alginate, methacylated/acrylated heparin, or any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the reinforced region comprises a hydrogel.

### Claim 11 (depends on 9)

The method of claim 9, wherein the monomer comprises methacrylated hyaluronic acid.

### Claim 12 (depends on 9)

The method of claim 9, wherein the reinforced region comprises a compressive modulus, an elastic modulus, or both, that is greater than that property of native cardiac tissue.

### Claim 13 (depends on 12)

The method of claim 12, wherein the reinforced region comprises a compressive modulus, an elastic modulus, or both, that is between 1.1 and 10 times that property of native cardiac tissue.

### Claim 14 (depends on 1)

The method of claim 1, wherein the reinforced region improves cardiac function relative to unreinforced cardiac tissue.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cardiac function comprises normalized end diastolic volume, normalized end systolic volume, ejection fraction, or any combination thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the monomer is delivered epicardially.

### Claim 17 (depends on 1)

The method of claim 1, wherein the monomer is delivered endocardially.

### Claim 18 (depends on 1)

The method of claim 1, wherein the polymerization is effected by an initiator.

### Claim 19 (depends on 18)

The method of claim 18, wherein the initiator comprises tetramethylethylenediamine

### Claim 20

A kit, comprising:
an injector adapted to deliver fluid to cardiac tissue;
a quantity of polymerizable material, the polymerizable material being selected for delivery to cardiac tissue.

### Claim 21 (depends on 20)

The kit of claim 20, wherein the polymerizable material is loaded into the injector.

### Claim 22 (depends on 20)

The kit of claim 20, wherein the polymerizable material comprises methacrylated hyaluronic acid, methacrylated/acrylated poly(ethylene glycol), acrylated poly(ethylene glycol), methacrylated/acrylated poly(vinyl alcohol), methacrylated/acrylated chitosan, metahcrylated/acrylated cellulose, poly(n-isopropryl acrylamide), methacrylated/acrylated alginate, methacylated/acrylated heparin, or any combination thereof.

### Claim 23 (depends on 22)

The kit of claim 22, further comprising a quantity of crosslinker, a quantity of initiator, or both.

### Claim 24 (depends on 20)

The kit of claim 20, further comprising two portions of polymerizable material, the two portions differing from one another in monomer concentration.

### Claim 25 (depends on 20)

The kit of claim 20, further comprising a growth factor, a protease inhibitor, a stem cell, a platelet factor, platelets, plasma components, or any combination thereof.
